Cancienne Jourdan M, Gwathmey F Winston, Werner Brian C
Department of Orthopaedic Surgery, University of Virginia Health System, Charlottesville, Virginia, U.S.A.
Department of Orthopaedic Surgery, University of Virginia Health System, Charlottesville, Virginia, U.S.A..
Arthroscopy. 2016 Jan;32(1):90-5. doi: 10.1016/j.arthro.2015.09.003. Epub 2015 Nov 6.
To employ a national database of Medicare patients to evaluate the association of ipsilateral intra-articular knee corticosteroid injections at the time of knee arthroscopy with the incidence of postoperative infection.
A national Medicare insurance database was queried for patients who underwent ipsilateral intra-articular corticosteroid injection of the knee at the time of knee arthroscopy from 2005 to 2012. Patients who underwent arthroscopically assisted open procedures, those who underwent more complex arthroscopic procedures, and those for whom laterality were not coded were excluded. This study group was compared to a control cohort of patients without intraoperative steroid injections that was matched to the study group for age, gender, obesity, diabetes mellitus, and smoking status. Infection rates within 3 and 6 months postoperatively were assessed using International Classification of Diseases, 9th Revision, and Current Procedural Terminology codes.
The incidence of postoperative infection rates after knee arthroscopy was significantly higher at 3 months (0.66%; odds ratio [OR], 2.6; P < .0001) and 6 months (1.92%; OR, 3.6; P < .0001) in patients who underwent ipsilateral intra-articular knee steroid injection at the time of knee arthroscopy (n = 2,866) compared with matched controls without intraoperative injections (n = 170,350) at 3 months (0.25%) and 6 months (0.54%).
The present study demonstrates a significant increase in postoperative infection in Medicare patients who underwent ipsilateral intra-articular knee corticosteroid injections at the time of knee arthroscopy compared with a matched control group without intraoperative injection.
Therapeutic Level III, retrospective comparative study.
利用医疗保险患者的全国性数据库,评估膝关节镜检查时同侧膝关节腔内注射皮质类固醇与术后感染发生率之间的关联。
查询2005年至2012年期间在膝关节镜检查时接受同侧膝关节腔内皮质类固醇注射的患者的全国医疗保险数据库。排除接受关节镜辅助开放性手术的患者、接受更复杂关节镜手术的患者以及未编码侧别的患者。将该研究组与未进行术中类固醇注射的对照组进行比较,对照组在年龄、性别、肥胖、糖尿病和吸烟状况方面与研究组相匹配。使用国际疾病分类第9版和现行手术操作术语编码评估术后3个月和6个月内的感染率。
与未进行术中注射的匹配对照组(n = 170,350)相比,在术后3个月(0.25%)和6个月(0.54%)时,膝关节镜检查时接受同侧膝关节腔内类固醇注射的患者(n = 2,866)术后感染率在3个月时显著更高(0.66%;优势比[OR],2.6;P <.0001),在6个月时也显著更高(1.92%;OR,3.6;P <.0001)。
本研究表明,与未进行术中注射的匹配对照组相比,膝关节镜检查时接受同侧膝关节腔内皮质类固醇注射的医疗保险患者术后感染显著增加。
治疗性III级,回顾性比较研究。